

Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine

NCT06603558

Status RECRUITING
Sponsor AbbVie
Enrollment 3,000 participants

Key Eligibility Criteria

Inclusion (2)

- Participants with migraine suitable for the treatment with atogepant according to the latest approved local label.
- Participants prescribed atogepant in accordance with the approved local label.

Exclusion (2)

- Participants with any contraindication to atogepant as listed on the latest approved local label.
- Participants currently participating in another clinical research except observational study.

Locations (4 total)

Hallym University Dongtan Sacred Heart Hospital /ID# 273581, Hwaseong, Gyeonggi-do, South Korea
Seoul National University Hospital /ID# 271892, Seoul, Seoul Teugbyeolsi, South Korea
Kangbuk Samsung Hospital /ID# 271893, Seoul, Seoul Teugbyeolsi, South Korea
... and 1 more locations